Hubei Biocause Pharmaceutical (SHE:000627) — Stock Price

CN¥1.58 CNY
▲ 0.00% today

Hubei Biocause Pharmaceutical (SHE:000627) is currently trading at CN¥1.58 CNY, up 0.00% today. Over the past 52 weeks, shares have ranged between CN¥1.56 and CN¥1.58. This page tracks Hubei Biocause Pharmaceutical's live share price on the SHE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see how much is Hubei Biocause Pharmaceutical worth.

Hubei Biocause Pharmaceutical (000627) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Hubei Biocause Pharmaceutical's daily closing share price and trading volume on the SHE exchange over the past year, giving a clear view of recent price momentum and liquidity.

Hubei Biocause Pharmaceutical Income Statement — Revenue, Profit & Earnings by Year

Hubei Biocause Pharmaceutical's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20232022202120202019
Total Revenue CN¥49.59 Billion CN¥49.62 Billion CN¥12.20 Billion CN¥12.30 Billion CN¥12.62 Billion
Cost of Revenue CN¥9.83 Billion CN¥8.46 Billion CN¥2.93 Billion CN¥2.87 Billion CN¥3.28 Billion
Gross Profit CN¥39.87 Billion CN¥41.16 Billion CN¥9.27 Billion CN¥9.43 Billion CN¥9.33 Billion
Research & Development — — — CN¥0.00 CN¥5.66 Million
SG&A CN¥896.78 Million CN¥333.97 Million CN¥2.24 Billion CN¥2.15 Billion CN¥600.75 Million
Total Operating Expenses CN¥27.99 Billion CN¥18.62 Billion CN¥11.67 Billion CN¥35.69 Billion CN¥-8.43 Billion
Operating Income CN¥21.71 Billion CN¥31.00 Billion CN¥526.31 Million CN¥-23.38 Billion CN¥21.05 Billion
EBITDA — CN¥31.16 Billion CN¥674.25 Million CN¥-23.30 Billion CN¥21.13 Billion
EBIT — CN¥245.59 Million CN¥300.64 Million CN¥1.10 Billion CN¥3.44 Billion
Interest Expense — CN¥1.86 Billion CN¥52.11 Million CN¥225.48 Million CN¥0.00
Income Before Tax CN¥-1.87 Billion CN¥224.78 Million CN¥343.12 Million CN¥1.45 Billion CN¥3.63 Billion
Income Tax Expense — CN¥-49.27 Million CN¥-537.09 Million CN¥331.56 Million CN¥714.89 Million
Net Income CN¥-651.76 Million CN¥274.05 Million CN¥470.71 Million CN¥580.29 Million CN¥1.78 Billion

Hubei Biocause Pharmaceutical Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Hubei Biocause Pharmaceutical's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20232022202120202019
Total Assets CN¥301.94 Billion CN¥288.60 Billion CN¥263.90 Billion CN¥239.40 Billion CN¥205.27 Billion
Total Current Assets CN¥50.67 Billion CN¥55.98 Billion CN¥49.46 Billion CN¥50.90 Billion CN¥25.16 Billion
Cash & Equivalents — — — — —
Short-term Investments CN¥1.80 Billion CN¥2.08 Billion CN¥2.91 Billion CN¥3.56 Billion CN¥2.21 Billion
Net Receivables CN¥77.20 Million CN¥82.68 Million CN¥3.58 Billion CN¥15.93 Million CN¥1.51 Billion
Inventory CN¥4.13 Billion CN¥10.50 Billion CN¥10.22 Billion CN¥10.72 Billion CN¥3.67 Billion
Property, Plant & Equipment — — CN¥830.33 Million CN¥580.44 Million CN¥567.17 Million
Goodwill CN¥6.19 Billion CN¥6.19 Billion CN¥6.19 Billion CN¥6.19 Billion CN¥6.19 Billion
Total Liabilities CN¥268.30 Billion CN¥254.00 Billion CN¥226.43 Billion CN¥204.81 Billion CN¥170.92 Billion
Total Current Liabilities CN¥24.46 Billion CN¥24.99 Billion CN¥13.06 Billion CN¥8.02 Billion CN¥8.43 Billion
Long-term Debt CN¥7.10 Billion CN¥6.79 Billion CN¥6.09 Billion CN¥2.76 Billion —
Net Debt — CN¥1.67 Billion — — —
Total Stockholder Equity CN¥20.59 Billion CN¥21.41 Billion CN¥22.55 Billion CN¥21.13 Billion CN¥21.22 Billion
Retained Earnings CN¥5.31 Billion CN¥6.51 Billion CN¥6.53 Billion CN¥6.11 Billion CN¥6.03 Billion

Hubei Biocause Pharmaceutical Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Hubei Biocause Pharmaceutical generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20232022202120202019
Operating Cash Flow CN¥9.53 Billion CN¥7.52 Billion CN¥4.17 Billion CN¥21.42 Billion CN¥28.60 Billion
Capital Expenditures CN¥67.53 Million CN¥135.06 Million CN¥287.13 Million CN¥319.51 Million CN¥717.10 Million
Free Cash Flow CN¥9.47 Billion CN¥7.39 Billion CN¥3.89 Billion CN¥21.11 Billion CN¥27.88 Billion
Investing Cash Flow — — CN¥-15.38 Billion CN¥-7.68 Billion CN¥-35.04 Billion
Financing Cash Flow — — CN¥7.62 Billion CN¥172.59 Million CN¥1.13 Billion
Dividends Paid CN¥1.41 Billion CN¥699.42 Million CN¥381.32 Million CN¥633.98 Million CN¥242.12 Million
Stock-Based Compensation — — — — —
Depreciation CN¥152.37 Million CN¥147.27 Million CN¥133.94 Million CN¥63.66 Million CN¥79.17 Million
Change in Cash CN¥1.84 Billion CN¥3.06 Billion CN¥-3.61 Billion CN¥13.88 Billion CN¥-5.32 Billion

Hubei Biocause Pharmaceutical Earnings History — EPS Actual vs. Analyst Estimates

Track Hubei Biocause Pharmaceutical's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
May 23, 2025 — — —
Sep 30, 2024 0.01 — —
Jun 30, 2024 -0.06 — —
May 24, 2024 -0.02 — —
Jan 29, 2024 -0.09 — —
Sep 30, 2023 -0.01 — —
Jun 30, 2023 -0.05 — —
Mar 31, 2023 0.01 — —